Home Newsfeeds BTIG Downgrades Retail Opportunity to Neutral

BTIG Downgrades Retail Opportunity to Neutral

BTIG analyst Michael Gorman downgrades Retail Opportunity (NASDAQ:ROIC) from Buy to Neutral.

byBenzinga Newsdesk

January 11, 2023

1 minute read

BTIG analyst Michael Gorman downgrades Retail Opportunity (NASDAQ:ROIC) from Buy to Neutral.

EXCLUSIVE: Cannabis Catalysts Praise SAFER Momentum, Plus State Market Prospects

By Lara Goldstein

September 27, 4:53 PM

The cannabis industry is poised for some serious growth owing to the historic clearance of the SAFER Banking Act by the

TCNNF

Cannabis Shops To Consumption Lounges, Google Ranks San Francisco’s Favorites

By Jelena Martinovic

June 28, 11:49 AM

It's clear that San Francisco has wholly accepted cannabis use, evidenced by the numerous cannabis-related locations around the city, making it easily accessible for both medical and recreational use.

GOOG

Mosaic Q3 Adj. EPS $3.22 Misses $3.42 Estimate, Sales $5.35B Miss $5.76B Estimate

By Michael Horton

November 7, 5:24 PM

Mosaic (NYSE:MOS) reported quarterly earnings of $3.22 per share which missed the analyst consensus estimate of $3.42 by 5.85 percent. This is a 138.52 percent increase over earnings of $1.35 per share from the same

MOS

180 Life Sciences Corp. Announces The Filing Of A Provisional Patent Describing The Combination Of CBD With GLP-1 Agonists To Suppress Appetite

By Happy Mohamed

July 31, 8:04 AM

180 Life Sciences Corp. (NASDAQ:ATNF) ("180LS" or the "Company"), today announced the filing of a provisional patent describing the novel combination of CBD, or an analog thereof, with glucagon

ATNF

BTIG Downgrades Retail Opportunity to Neutral

Related Posts

EXCLUSIVE: Cannabis Catalysts Praise SAFER Momentum, Plus State Market Prospects

Cannabis Shops To Consumption Lounges, Google Ranks San Francisco’s Favorites

Mosaic Q3 Adj. EPS $3.22 Misses $3.42 Estimate, Sales $5.35B Miss $5.76B Estimate

180 Life Sciences Corp. Announces The Filing Of A Provisional Patent Describing The Combination Of CBD With GLP-1 Agonists To Suppress Appetite